Name | Number of supported studies | Average coverage | |
---|---|---|---|
basal cell | 4 studies | 30% ± 14% | |
neutrophil | 3 studies | 26% ± 4% |
Insufficient scRNA-seq data for expression of HCAR2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 80% | 600.17 | 463 / 578 | 72% | 17.65 | 827 / 1155 |
bladder | 43% | 252.05 | 9 / 21 | 70% | 20.53 | 355 / 504 |
breast | 77% | 513.23 | 354 / 459 | 29% | 1.96 | 325 / 1118 |
esophagus | 39% | 891.97 | 565 / 1445 | 66% | 15.72 | 120 / 183 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.67 | 1 / 1 |
spleen | 98% | 1014.64 | 237 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 45.26 | 44 / 45 |
adipose | 83% | 732.89 | 1001 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 81% | 5387.72 | 751 / 929 | 0% | 0 | 0 / 0 |
skin | 71% | 1212.52 | 1291 / 1809 | 8% | 0.62 | 38 / 472 |
kidney | 62% | 220.99 | 55 / 89 | 11% | 1.08 | 96 / 901 |
prostate | 40% | 196.69 | 98 / 245 | 31% | 1.82 | 157 / 502 |
uterus | 2% | 25.94 | 4 / 170 | 66% | 30.47 | 303 / 459 |
pancreas | 0% | 0 | 0 / 328 | 29% | 5.68 | 52 / 178 |
stomach | 9% | 45.97 | 33 / 359 | 19% | 2.72 | 55 / 286 |
intestine | 4% | 15.37 | 37 / 966 | 22% | 2.55 | 117 / 527 |
thymus | 2% | 4.38 | 12 / 653 | 20% | 3.83 | 124 / 605 |
ovary | 0% | 0 | 0 / 180 | 9% | 0.53 | 40 / 430 |
liver | 5% | 13.66 | 11 / 226 | 4% | 0.34 | 17 / 406 |
blood vessel | 5% | 22.74 | 73 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.57 | 1 / 29 |
heart | 3% | 10.55 | 29 / 861 | 0% | 0 | 0 / 0 |
brain | 0% | 0.76 | 9 / 2642 | 2% | 0.14 | 17 / 705 |
adrenal gland | 0% | 0.83 | 1 / 258 | 1% | 0.07 | 2 / 230 |
muscle | 0% | 1.09 | 3 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0033031 | Biological process | positive regulation of neutrophil apoptotic process |
GO_0070165 | Biological process | positive regulation of adiponectin secretion |
GO_0001781 | Biological process | neutrophil apoptotic process |
GO_0050995 | Biological process | negative regulation of lipid catabolic process |
GO_0030054 | Cellular component | cell junction |
GO_0005886 | Cellular component | plasma membrane |
GO_0070553 | Molecular function | nicotinic acid receptor activity |
Gene name | HCAR2 |
Protein name | Hydroxycarboxylic acid receptor 2 Hydroxycarboxylic acid receptor 2 (G-protein coupled receptor 109A) (G-protein coupled receptor HM74A) (Niacin receptor 1) (Nicotinic acid receptor) |
Synonyms | NIACR1 HM74A HCA2 GPR109A |
Description | FUNCTION: Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide. . |
Accessions | ENST00000328880.6 A0A4Y1JWQ0 Q8TDS4 |